Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 10/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409880 | 1.00 | ECE1 (0.61) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7141433 | 0.89 | ECE1 (0.62) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL6977959 | 0.89 | ECE1 (0.62) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7148136 | 0.88 | ECE1 (0.64) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7148134 | 0.88 | ECE1 (0.64) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL5723229 | 0.87 | ECE1 (0.69) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7136604 | 0.86 | ECE1 (0.59) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7151710 | 0.86 | ECE1 (0.59) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7150595 | 0.83 | ECE1 (0.55) | ECE1MMEACEAKR1C3AKR1C1 | |
| SCHEMBL7150599 | 0.83 | ECE1 (0.55) | ECE1MMEACEAKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189756-B2 | Pyrrolidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | AEBI JOHANNES (CH) | 2004-12-02 | — | — | US | disclosed |
| US-6790860-B2 | USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199569-A1 | Pyrrolidine derivatives | AEBI JOHANNES (CH) | 2003-10-23 | — | — | US | disclosed |
| US-20020040146-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199569-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | ECE1 4/4885MME 100/4885ACE 85/4885 |
| US-20020040146-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | ECE1 4/4885MME 100/4885ACE 85/4885 |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | MMP1, PEPD, MMP25 | ECE1 33/4885MME 44/4885ACE 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.